Civica Rx is a nonprofit generic drug company that secures a stable, affordable supply of essential sterile injectable medicines for U.S. hospitals and health systems. By partnering with FDA‑approved manufacturers, developing its own ANDAs, and operating a large domestic manufacturing facility, it provides reliable, low‑cost drugs and extends access to consumers through its CivicaScript retail line.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
U.S. hospitals frequently face chronic shortages and price volatility of essential generic injectable medicines, which can disrupt patient care and increase treatment costs.
Solution
Civica Rx is a nonprofit, not‑for‑profit generic drug company created by a coalition of health systems and philanthropic foundations to secure a stable, affordable supply of critical generic medications. It sources drugs through FDA‑approved contract manufacturers, develops its own abbreviated new drug applications, and is building a state‑of‑the‑art sterile injectable manufacturing facility in Virginia to produce finished dosage forms domestically. By aggregating demand from over 50 health systems—representing more than 30 % of U.S. hospital beds—Civica leverages economies of scale to lower production costs and reduce reliance on volatile market pricing. The organization also operates CivicaScript, an outlet for affordable outpatient generics such as insulin, extending its mission beyond hospitals to consumers. Through these integrated supply‑chain strategies, Civica ensures predictable availability and fair pricing of essential medicines for patients and providers.
Target Audience
Primary customers are U.S. hospitals and health systems—including academic, community, and safety‑net facilities—that require reliable sterile injectable generics, as well as retail patients accessing affordable outpatient medicines through CivicaScript.
Features
- FDA‑approved contract manufacturing partnerships that enable rapid market entry of shortage drugs under the Civica National Drug Code
- Development and filing of ANDAs for key sterile injectables, allowing direct control over formulation and quality
- 120,000 sq ft Virginia manufacturing plant with automated filling lines, steam sterilization, visual inspection, and temperature‑controlled warehousing, capable of producing 90 M vials and 50 M pre‑filled syringes annually
- Three‑pronged supply model (partner manufacturing, in‑house ANDA development, own facility) providing redundancy and safety‑stock for critical medicines
- Nationwide distribution network serving over 1,350 hospitals, the VA, DoD, and 340B providers, ensuring broad access
- CivicaScript retail arm delivering affordable outpatient generics, including a planned low‑cost insulin product